The Study

Study aim

The aim of the study is the characterization of early airway function changes, and an assessment of the underlying mechanisms. This would allow us to develop and improve prevention and treatment strategies for children affected by CF. The following questions will be addressed within the scope of the study:

  • What parameters related to lung development can already be identified shortly after birth in lung function changes found in infancy?
  • What influence do viral infections of the respiratory tract have on lung development, lung growth, and overall respiratory  morbidity?
  • Which bacteria colonize the early airways?
  • Are there biomarkers in the expired breath that could tell us something about the bacterial colonization of the airways?

In order to compare the data from CF children with healthy controls, we also make use of data from the  BILD Cohort.

Cystic fibrosis

Cystic fibrosis (CF), also known as mucoviscidosis, is the most common inherited metabolic disease and affects some 2500 newborns.

In 2011, Switzerland began testing for CF in the newborn screenings (Guthrie Test). Approximately, 1,000 CF patients live in Switzerland.


CF most significantly affects the lungs.  Infections and inflamma-tion of the airways begin early in the life of CF patients, and can lead to a modification and reduction in lung function.  It is known that changes in lung structure that can affect lung function are already detectable shortly after birth.


For more infomation about CF please visit the following website  Swiss Society for Cystic Fibrosis CFCH.



Here you will find information about the requirements for participation, benefits, risks, data protection, and withdrawal from the study.  

Study procedure

What will be examined? What data will be collected and when?  


We are easy to find, whether you arrive by auto or public transportation.